Retatrutide making you poop more — or less — is one of the most commonly reported experiences in clinical trials of this investigational triple receptor agonist. By activating GLP-1, GIP, and glucagon receptors simultaneously, retatrutide exerts powerful effects on gut motility that can cause diarrhoea, constipation, nausea, and abdominal discomfort. Understanding why these bowel changes occur, how long they typically last, and when they require medical attention is essential for anyone taking retatrutide under specialist supervision or within a clinical trial. This article explains the mechanisms behind these effects and offers practical, evidence-based guidance aligned with NHS and NICE recommendations.

Why Retatrutide Can Affect Your Bowel Habits

Retatrutide alters bowel habits primarily through GLP-1 receptor activation, which slows gastric emptying and disrupts normal gut motility, causing diarrhoea or constipation depending on the individual.

Retatrutide is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor mechanism distinguishes it from earlier weight-management medicines such as semaglutide (Wegovy) or tirzepatide (Mounjaro), and it also explains why gastrointestinal effects — including changes to bowel habits — are among the most frequently reported experiences in clinical trials.

The GLP-1 component plays a particularly important role in gut function. GLP-1 receptors are found throughout the gastrointestinal tract, and their activation slows gastric emptying — the rate at which food moves from the stomach into the small intestine. This slowing effect can cause constipation in some individuals. Some people also experience diarrhoea or more frequent bowel movements, although the precise mechanism by which GLP-1 receptor agonists cause diarrhoea is not fully understood and is likely to involve multiple factors. The net effect varies considerably between individuals depending on their baseline gut motility, diet, hydration, and dose.

The contributions of GIP and glucagon receptor activation to bowel changes are not yet well characterised for retatrutide specifically, and any claims about their effects on gut motility or intestinal secretion remain uncertain given the medicine's investigational status.

It is important to understand that mild, transient bowel changes are a recognised pharmacological effect seen across the GLP-1 receptor agonist class. However, this does not mean all symptoms should be dismissed — severe or persistent symptoms can indicate complications and always warrant medical review. Retatrutide is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and should only be used under specialist supervision or within a formal clinical trial.

Common Gastrointestinal Side Effects Explained

Nausea, diarrhoea, vomiting, and constipation are the most common gastrointestinal side effects of retatrutide, reported in up to 60% of Phase 2 trial participants and increasing with higher doses.

Clinical trial data for retatrutide, including Phase 2 results published in the New England Journal of Medicine (Jastreboff et al., 2023), identified gastrointestinal adverse events as the most common side effects reported by participants. In that trial, nausea was reported in approximately 45–60% of participants (varying by dose), diarrhoea in approximately 30–40%, vomiting in approximately 20–30%, and constipation in a smaller proportion. These events were generally mild to moderate in severity and included:

• Nausea — often accompanying changes in bowel habits, particularly after dose escalation

• Diarrhoea — loose or watery stools, sometimes with urgency

• Vomiting — less common but reported, especially at higher doses

• Constipation — occurring in some individuals, reflecting the variable effect on gut motility

• Abdominal discomfort or bloating — a sensation of fullness or cramping

• Flatulence — increased wind, which can accompany altered digestion

Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 5–10% of participants depending on dose group. The incidence of these effects increased with higher doses, consistent with the dose-dependent pharmacology of GLP-1 receptor agonists as a class.

Although GI symptoms are expected, it is important to be aware of rarer but more serious class-related risks. These include pancreatitis (inflammation of the pancreas) and gallbladder disease (including gallstones and cholecystitis), both of which are recognised warnings in the prescribing information for licensed GLP-1 receptor agonists such as semaglutide and tirzepatide. Dehydration from persistent diarrhoea or vomiting can also lead to acute kidney injury, particularly in people with pre-existing kidney conditions. These risks are discussed further in the red-flag section below.

Because retatrutide remains unlicensed, its full side-effect profile is still being characterised. Patients should only access it through a formal clinical trial or under specialist medical oversight, and must not obtain it from unregulated online sources, where product safety and authenticity cannot be guaranteed.

How Long Digestive Symptoms Typically Last

Digestive symptoms are usually most pronounced during early treatment and dose escalation, often settling within four to eight weeks at a stable dose, though this varies between individuals.

For most people taking GLP-1-based therapies — including retatrutide — gastrointestinal symptoms tend to be most pronounced during the early weeks of treatment and during periods of dose escalation. This pattern is well-established across the drug class and is thought to reflect the gut's gradual adaptation to altered motility signals.

In the retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023), many participants found that symptoms such as diarrhoea, nausea, and abdominal discomfort improved after the initial weeks at a given dose, consistent with experience seen with licensed GLP-1 receptor agonists. Based on class experience, symptoms often begin to settle within four to eight weeks at a stable dose, though this is not guaranteed for every individual. Each time the dose is increased — as is typical in structured escalation protocols — symptoms may temporarily return or worsen before settling again.

As a practical guide: if gastrointestinal symptoms persist beyond two to four weeks at a stable dose, are significantly affecting your ability to eat, drink, or carry out daily activities, or are causing signs of dehydration, you should contact your prescriber rather than waiting for symptoms to resolve on their own.

A proportion of participants in the retatrutide trial discontinued treatment due to gastrointestinal side effects that did not resolve. This underscores the importance of not assuming all symptoms will self-resolve, particularly if they are severe or persistent. Individual responses vary based on gut sensitivity, dietary habits, hydration, and the rate of dose escalation.

Keeping a simple symptom diary — noting the frequency, consistency, and timing of bowel changes relative to your injections and meals — is strongly recommended. This information is invaluable when discussing symptom management with your prescriber and can help distinguish expected pharmacological effects from symptoms that warrant further investigation.

Managing Bowel Changes Whilst Taking Retatrutide

Eating smaller meals, staying well hydrated, and avoiding high-fat foods are first-line strategies; oral rehydration salts and macrogol laxatives may help, but always seek pharmacist or GP advice before use.

Several practical strategies may help reduce the impact of bowel-related side effects whilst continuing retatrutide treatment. These are broadly consistent with guidance used for other GLP-1 receptor agonists and with NICE and NHS self-care advice for diarrhoea and constipation.

Dietary adjustments are often the first line of self-management:

• Eat smaller, more frequent meals rather than large portions

• Avoid high-fat, greasy, or heavily spiced foods, which can exacerbate loose stools

• Reduce intake of foods known to cause wind, such as beans, cruciferous vegetables, and carbonated drinks

• If constipation is the predominant symptom, increase soluble fibre gradually — sudden large increases in fibre can worsen bloating and discomfort

• Stay well hydrated, particularly if experiencing diarrhoea, to prevent dehydration

Timing and lifestyle considerations can also make a meaningful difference. Some individuals find that taking their injection on a day when they can rest and monitor their response is helpful, particularly during dose escalation. Avoiding strenuous exercise immediately after eating may reduce abdominal discomfort.

Over-the-counter remedies may be appropriate in some cases, but should only be used after discussion with a pharmacist or GP:

• Oral rehydration salts (such as Dioralyte) are recommended for diarrhoea-related fluid loss

• Loperamide may be considered for short-term management of loose stools, but must be avoided if you have a fever, blood or mucus in your stools, or if antibiotic-associated diarrhoea (including Clostridioides difficile) is suspected — seek pharmacist or GP advice first

• For constipation, macrogol-based laxatives (such as Movicol) are a reasonable first-line option in line with NICE CKS guidance on constipation in adults; stimulant laxatives should generally be used only on professional advice

Interactions with other medicines: GLP-1 receptor agonists slow gastric emptying, which can affect the absorption of some oral medicines. If you take oral contraceptives, discuss this with your prescriber or pharmacist, as the prescribing information for tirzepatide (a related medicine) advises considering additional or alternative contraceptive methods during initiation and dose escalation. This precaution may apply by class to retatrutide, though specific data are not yet available.

If you have diabetes: periods of reduced food intake, diarrhoea, or vomiting can increase the risk of hypoglycaemia if you are also taking insulin or a sulphonylurea. Monitor your blood glucose more closely during these periods and seek advice from your diabetes team.

It is important not to self-adjust the dose of retatrutide without medical advice. If symptoms are intolerable, your prescriber may recommend slowing the dose-escalation schedule, which is a recognised and effective strategy for improving tolerability across the GLP-1 drug class.

When to Seek Medical Advice About Digestive Side Effects

Seek prompt medical attention for diarrhoea lasting over 48–72 hours, signs of dehydration, blood in stools, or severe abdominal pain, which may indicate pancreatitis, gallbladder disease, or intestinal obstruction.

Whilst mild and transient bowel changes are an expected feature of retatrutide treatment, certain symptoms should prompt timely medical attention. Knowing when to escalate concern is an important aspect of safe self-management.

Contact your GP or prescriber promptly if you experience:

• Diarrhoea lasting more than 48–72 hours without improvement

• Signs of dehydration, including dark urine, dizziness, dry mouth, or reduced urination — dehydration can lead to acute kidney injury, particularly in people with pre-existing kidney conditions

• Blood or mucus in your stools, or rectal bleeding

• Severe or worsening abdominal pain, particularly if localised, persistent, or accompanied by fever

• Persistent vomiting that prevents you from keeping fluids down

• Rapid, symptomatic, or disproportionate weight loss accompanied by systemic symptoms such as fatigue or fever — this is distinct from the expected gradual weight loss associated with treatment and should be discussed with your prescriber

• Symptoms that are substantially affecting your ability to work, sleep, eat, or carry out daily activities

Seek urgent medical assessment if you develop:

• Severe, persistent abdominal pain — particularly pain radiating to the back — which may indicate pancreatitis. Pancreatitis is a recognised class warning for GLP-1 receptor agonists, as noted in the prescribing information (SmPCs) for semaglutide and tirzepatide and in MHRA Drug Safety communications. A direct causal link with retatrutide has not yet been formally established, but the risk cannot be excluded

• Right upper quadrant pain, fever, or jaundice (yellowing of the skin or eyes), which may suggest gallbladder disease (such as gallstones or cholecystitis) — another recognised class-related risk

• Severe constipation with vomiting, abdominal distension, and inability to pass wind, which may indicate intestinal obstruction or ileus and requires urgent assessment

• Symptoms that feel disproportionate or different in character from typical digestive upset

In an emergency, contact NHS 111 or attend your nearest accident and emergency department. Do not delay seeking help out of concern that your symptoms are simply a side effect.

If you develop a persistent, unexplained change in bowel habit — particularly if you are aged 40 or over or have other risk factors — your GP may wish to assess you in line with NICE guidance on suspected cancer (NG12), which sets out referral thresholds for persistent bowel changes.

Talking to Your GP or Prescriber About Your Symptoms

Bring a symptom diary to appointments and describe onset, frequency, and severity; your prescriber may adjust your dose schedule, recommend dietary changes, or refer you to a gastroenterologist.

Open communication with your GP or prescriber is essential when managing gastrointestinal side effects from retatrutide. Because retatrutide is not licensed in the UK, patients should only access it through a formal clinical trial or under specialist medical oversight. It must not be obtained from unregulated online suppliers, where product safety, authenticity, and appropriate dosing cannot be assured. If you are unsure about the legitimacy of your supply, speak to your GP or a registered specialist.

When attending an appointment, it helps to come prepared. Bring your symptom diary if you have kept one, and be ready to describe:

• When symptoms began in relation to starting or increasing the dose

• How often you are experiencing bowel changes and what they look like

• Whether symptoms are improving, worsening, or staying the same

• What you have already tried to manage them and whether it helped

• How much the symptoms are affecting your daily life and wellbeing

Your prescriber may consider adjusting your dose-escalation schedule, recommending specific dietary changes, or referring you to a gastroenterologist if symptoms are complex or persistent. They may also wish to rule out other causes of bowel changes unrelated to retatrutide. Depending on your symptoms, this might include blood tests (including coeliac serology), stool cultures, or faecal calprotectin measurement to help distinguish drug-related effects from conditions such as irritable bowel syndrome, coeliac disease, inflammatory bowel disease, or infection.

Retatrutide is not recommended during pregnancy or breastfeeding. If you are pregnant, planning a pregnancy, or breastfeeding, inform your prescriber immediately so that your treatment can be reviewed.

Suspected adverse drug reactions to retatrutide can be reported through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Both patients and healthcare professionals can submit reports. Doing so contributes to the broader evidence base and helps improve safety monitoring for emerging treatments such as retatrutide.

Frequently Asked Questions